Repligen(NASDAQ) RGEN

Repligen Corporation makes tools used to manufacture biological medicines. These tools help drug companies create treatments for many diseases. They help make drug production faster and more efficient.

Essential Bioprocessing Technologies

• Filtration products: Filters used to concentrate and purify biological drugs; accounted for $95.7 million of product revenue in the three months ended June 30, 2026.
• Chromatography products: Tools such as pre-packed columns and resins for protein separation; generated $51.9 million of product revenue in the three months ended June 30, 2026.
• Process analytics products: Systems providing real-time data to monitor production; contributed $25.8 million of product revenue in the three months ended June 30, 2026.
• Proteins products: Binding elements and growth factors for biomanufacturing; provided $31.4 million of product revenue in the three months ended June 30, 2026.

Strategic Deals and Shifts

• Entered an agreement to acquire BioLife Solutions for approximately $1.5 billion in July 2026.
• Completed the acquisition of 908 Devices' desktop bioprocessing portfolio in March 2025.
• Divested the Polymem business in March 2026 to focus on core operations.

Bridging the Manufacturing Gap

Repligen maintains a broad portfolio serving both upstream and downstream manufacturing steps. Its systems integrate into existing workflows to improve flexibility and yield for drug developers.

Financial Performance Data

• Total revenue reached $204.1 million in the three months ended June 30, 2026, up 11.9% year over year.
• Gross margin increased to 53.9% in the three months ended June 30, 2026, compared to 51.0% in the same period in 2025.
• Cash provided by operating activities was $61.1 million for the six-month period ended June 30, 2026.
• Total liquidity reached $810.4 million as of June 30, 2026.

Evolution of the Business

Repligen has transitioned into a comprehensive provider of bioprocessing technologies through strategic acquisitions and internal innovation. This evolution allows it to support the entire production cycle of modern biological medicines.